Bristol-Myers Squibb raised its 2025 EPS outlook after a Q1 beat, with shares trading far below historical P/E levels. Find ...

This revenue marks a 6% decline year-over-year from the same timeframe last year, during which the company recorded a loss of ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably ...

This morning, we reported record first quarter consolidated revenue of $251 million, which was 4.5% higher than the prior ... It has been accepted by the EU, and they are reviewing it.

4% NFD), which will strengthen their alliance to co-invest around €5 000 million in this facility. Assessment: News with little impact. Although yet to be confirmed, it would be part of Iberdrola’s ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Consensus $6.74. Raises FY25 revenue view to $45.8B-$46.8B from $45.5B, consensus $45.8B. The company states: “The company is increasing its ...

We recently published a list of 10 Stocks to Watch as Trade Wars Begin. In this article, we are going to take a look at where ...

The EU on Wednesday slapped Apple and Meta with 700 million euros in fines for breaking digital competition rules, risking the wrath of US President Donald Trump. The penalties threaten to cause ...